- Home
- SRTAW vs LEXX Comparison
SRTAW vs LEXX Comparison
Compare SRTAW & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTAW
- LEXX
- Stock Information
- Founded
- SRTAW N/A
- LEXX 2004
- Country
- SRTAW United States
- LEXX Canada
- Employees
- SRTAW N/A
- LEXX N/A
- Industry
- SRTAW
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- SRTAW
- LEXX Health Care
- Exchange
- SRTAW Nasdaq
- LEXX Nasdaq
- Market Cap
- SRTAW 16.3M
- LEXX 16.5M
- IPO Year
- SRTAW 2019
- LEXX N/A
- Fundamental
- Price
- SRTAW $0.15
- LEXX $1.03
- Analyst Decision
- SRTAW
- LEXX Strong Buy
- Analyst Count
- SRTAW 0
- LEXX 1
- Target Price
- SRTAW N/A
- LEXX $4.00
- AVG Volume (30 Days)
- SRTAW N/A
- LEXX 187.7K
- Earning Date
- SRTAW N/A
- LEXX 07-14-2025
- Dividend Yield
- SRTAW N/A
- LEXX N/A
- EPS Growth
- SRTAW N/A
- LEXX N/A
- EPS
- SRTAW N/A
- LEXX N/A
- Revenue
- SRTAW N/A
- LEXX $615,923.00
- Revenue This Year
- SRTAW N/A
- LEXX $46.98
- Revenue Next Year
- SRTAW N/A
- LEXX $17.26
- P/E Ratio
- SRTAW N/A
- LEXX N/A
- Revenue Growth
- SRTAW N/A
- LEXX 49.85
- 52 Week Low
- SRTAW N/A
- LEXX $0.77
- 52 Week High
- SRTAW N/A
- LEXX $3.72
- Technical
- Relative Strength Index (RSI)
- SRTAW N/A
- LEXX 63.07
- Support Level
- SRTAW N/A
- LEXX $0.86
- Resistance Level
- SRTAW N/A
- LEXX $1.09
- Average True Range (ATR)
- SRTAW 0.00
- LEXX 0.08
- MACD
- SRTAW 0.00
- LEXX 0.02
- Stochastic Oscillator
- SRTAW 0.00
- LEXX 81.47
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.